Medical Oncology

EGFR+

Questions discussed in this category

How do you counsel patients with Stage IIIA EGFR+ lung cancer regarding treatment intent with concurrent chemoRT + consolidative systemic therapy?

With low #s of patients on the durvalumab PACIFIC trial with EGFR mutated disease, and LAURA trial design of osimertinib until progression, should we ...

3 Answers available

How do you sequence targeted therapy and immunotherapy in patients with metastatic lung adenocarcinoma with EGFR exon 20 insertion mutations?

1 Answer available

Are you offering durvalumab to patients with Stage III NSCLC with known targeted mutations (ie ALK, EGFR, ROS1, BRAF) after completion of chemoradiation per PACIFIC?

2 Answers available

What systemic therapy would you offer to a patient with metastatic EGFR exon 19 deleted NSCLC to the brain with isolated CNS progression while on osimertinib 80 mg and progressed through WBRT?

Do you consider dose escalating to 160 mg or do you add chemotherapy to osimertinib?

1 Answer available

How many days do you hold osimertinib during or around SBRT for oligometastatic EGFR mutated advanced lung cancer?

Does the site of treatment factor into your decision?

2 Answers available

Would you offer adjuvant osimertinib in a patient with complete pathologic response to neoadjuvant platinum doublet for a stage IIIA resected EGFR mutant lung adenocarcinoma?

2 Answers available

Are there any data regarding safety or efficacy of osimertinib and concurrent chemotherapy in patients with metastatic NSCLC harboring sensitizing EGFR mutation?

1 Answer available

Do you consider using 160 mg osimertinib in patients with EGFR-positive metastatic NSCLC to the brain?

1 Answer available

How would you treat a potentially resectable stage III lung adenocarcinoma with an EGFR mutation?

Do you consider any neoadjuvant therapy or proceed to surgery followed by adjuvant chemotherapy and osimertinib? Does the type of mutation (ex a rare ...

1 Answer available

Based on results from ADAURA, in clinical practice, how likely are you to recommend adjuvant chemotherapy prior to adjuvant osimertinib for stage IIA T2bN0 EGFR mutant NSCLC?

1 Answer available

Should osimertinib be held prior to yttrium 90 liver directed therapy?

1 Answer available

Would you still offer adjuvant osimertinib to patients who elect not to receive chemotherapy in resected EGFR mutated lung cancer?

1 Answer available

What adjuvant therapy would you offer following adjuvant chemotherapy for a patient with Stage III lung adenocarcinoma with an atypical EGFR mutation such as EGFR L861R?

Would you offer adjuvant atezolizumab, osimertinib, or neither? Both IMpower010 and ADAURA only had patients with EGFR exon 19 deletion or L858R mutat...

1 Answer available

Would you hold osimertinib in a patient with a STEMI, and for how long?

1 Answer available

Would you offer adjuvant chemotherapy, osimertinib, or both to a patient with Stage IB EGFR mutated lung adenocarcinoma found in the lung explant pathology after bilateral lung transplant?

Would you consider the immune suppressed status of the patient as a high risk factor to offer adjuvant therapy?

1 Answer available

Do you avoid immunotherapy in patients with Stage IV NSCLC with atypical EGFR mutations such as G719S or S768I?

1 Answer available

How do you approach EGFR mutated NSCLC with isolated progression in the chest who is planned for a course of radiation at least 3-4 weeks?

How do you balance the risk of an EGFR flare while holding osimertinib vs the risk of pneumonitis when continuing?

1 Answer available

How would you treat a patient with stage 4 NSCLC with EGFR R776H mutation?

2 Answers available

What is your approach to a patient with an EGFR exon 19 mutated NSCLC who develops progression on osimertinib and repeat biopsy demonstrates the EGFR exon 19 mutation and a new BRAF V600E mutation?

1 Answer available

In locally advanced EGFR-mutated NSCLC with initial good response to osimertinib, how do you manage local progression of the primary?

Would you consider SBRT and continue osimertinib?

2 Answers available

Should 3 years of adjuvant osimertinib be the standard of care for resected Stage IB-IIIA EGFRm NSCLC?

6 Answers available

Are there any safety or efficacy data regarding the use of EGFR inhibitors in patients on hemodialysis for ESRD?

1 Answer available

Are there any subsets of patients where you would consider first-line dacomitinib for EGFR mutations positive NSCLC?

Are there specific mutations or co-mutations were you would consider use of this agent?

1 Answer available

Would you offer EGFR inhibitors to a patient with metastatic lung adenocarcinoma EGFR L858R mutation and concomitant NRAS mutation both on blood based testing?

1 Answer available

How would you treat a patient with metastatic NSCLC >50% PDL-1 positive AND an EGFR or ALK gene mutation/rearrangement in the first-line setting?

1st-line pembrolizumab is supposed to be used AFTER failure of appropriate targeted agents in this setting, but would you consider the reverse sequenc...

2 Answers available

How do you approach a patient who responded to first line osimertinib but develop an isolated progressing lesion that retains sensitizing EGFR mutation but develops MET amplification?

Would you continue osimertinib after radiation therapy, switch to crizotinib, or consider chemotherapy +/- immunotherapy?

1 Answer available

Do you use a TKI for resected EGFR+ non-small cell lung cancer?

In IB-IIIA cases?

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2015-10-22

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2016-11-10

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

J Thorac Oncol,

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.

Clin. Cancer Res., 2015 May 27

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.

Lancet (London, England), 2017-01-21

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Lancet (London, England), 2016-04-09

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

The New England journal of medicine, 2018-06-14

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

The Lancet. Respiratory medicine, 2019-05

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

Ann. Oncol.,

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.

The New England journal of medicine, 2018-12-13

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

J. Clin. Oncol., 2019 Dec 11

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).

Lancet Oncol., 2017 Sep 25

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-12-01

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

N Engl J Med, 2020 Sep 19

Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.

J Clin Oncol, 2020 Dec 04

Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.

Clin Oncol (R Coll Radiol), 2017 Nov 16

Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014-06

Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy.

Radiother Oncol, 2020 Jul 31

An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib.

The Lancet. Oncology, 2015-07

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-08-01

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

J BUON,

Chromosome 7 deregulation in non-small cell lung carcinoma molecular landscape.

Br J Cancer, 2019 Sep 30

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.

Biochemistry, 2015 Jul 06

Mechanistic Insights into R776H Mediated Activation of Epidermal Growth Factor Receptor Kinase.

N Engl J Med, 2019 Nov 21

Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.

Lancet Oncol, 2016 Apr 12

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013-01

Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.

Future Oncol, 2018 Nov 08

Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing.

World J Clin Cases,

Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report.

Br J Cancer, 2016 Nov 22

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2011-10-01

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-01

A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG).

Lung Cancer, 2020 Nov 13

Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib.

Neuropathology, 2019 Mar 13

Rapidly progressive miliary brain metastasis of lung cancer after EGFR tyrosine kinase inhibitor discontinuation: An autopsy report.

Respir Investig, 2014 Nov 13

Disease flare after gefitinib discontinuation.

JACC CardioOncol, 2019 Dec 17

Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS).

J. Clin. Oncol., 2008-07-20

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

J Clin Oncol, 2021 Nov 02

Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With Mutation (IMPACT).

Lancet, 2021 Sep 20

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.

FEBS J, 2009 Nov 18

Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.

Clin Lung Cancer, 2018 May 01

ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.

J Thorac Oncol, 2021 Feb 01

Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.

ESMO Open, 2021 Sep 17

Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study.

J Clin Oncol, 2019 Dec 06

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.

Ann Oncol, 2020 Jul 05

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.

J Thorac Oncol, 2021 Aug 19

A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L).

Clin Transl Sci, 2023 Feb 19

Brain exposure of osimertinib in patients with EGFRm NSCLC and brain metastases: a PET and MRI study.

N. Engl. J. Med.,

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

J Clin Oncol, 2011 Nov 28

Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer.

J Clin Oncol, 2019 Jun 13

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 -Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.

J Clin Oncol, 2022 Aug 12

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated .

J Thorac Oncol, 2023 Feb 23

Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC: A Post-Hoc Subgroup Analysis from PACIFIC.

Future Oncol, 2021 Jul 19

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for -mutated resectable non-small-cell lung cancer: NeoADAURA.

J Clin Oncol, 2023 Jan 31

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.

The Lancet. Oncology, 2014-01

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.

JTO clinical and research reports, 2022 Apr 21

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.

The New England journal of medicine, 2023 Nov 08

Osimertinib with or without Chemotherapy in -Mutated Advanced NSCLC.

The New England journal of medicine, 2024 Jun 02

Osimertinib after Chemoradiotherapy in Stage III -Mutated NSCLC.

The New England journal of medicine, 2018-01-11

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol, 2021 Aug 2

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.

The New England journal of medicine, 2023 Oct 21

Amivantamab plus Chemotherapy in NSCLC with Exon 20 Insertions.

Medical Oncology

EGFR+

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology